Search Results

Press Releases

Synedgen Promotes Dr. Laura Saward to Chief Executive Officer and Appoints Dr. Kenton Gregory to Chief Medical Officer

July 3, 2025

·

4 min read

Press Releases

Synedgen Announces Appointment of Dr. Laura Saward as Chief Scientific Officer

February 11, 2025

·

3 min read

Biotech Beach

Synedgen Completes IND-Enabling Studies for Two Parallel Programs for Lead Asset MIIST305

Synedgen, Inc. announced it has completed IND-enabling studies for its lead candidate, MIIST305.

April 25, 2024

·

4 min read

Press Releases

Synedgen Announces Gut Microbes Publication of Preclinical Data Showing MIIST305 Mitigates Gastrointestinal Acute Radiation Syndrome Injury in a Murine Model

February 26, 2025

·

3 min read

Press Releases

Synedgen Adds Dr. Hal J. Oien to its Board of Directors

September 24, 2024

·

2 min read

Press Releases

Synedgen Announces $2.2 Million JWMRP Award for MIIST305 For Use as a Prophylactic Radiation Medical Countermeasure

November 1, 2024

·

4 min read

Press Releases

Synedgen Receives Contract from BARDA to Develop MIIST305 as a Medical Countermeasure for Gastrointestinal Acute Radiation Syndrome

October 15, 2024

·

4 min read

Business

Synedgen Appoints Industry Veteran Dennis Fenton, Ph.D., to Board of Directors

Synedgen, a biopharma company dedicated to using its Multivalent Innate Immune Signaling Target (MIIST) platform to develop drugs that mimic and enhance the innate immune system, today announced that industry veteran Dennis Fenton, Ph.D., has joined Synedgen’s Board of Directors.

February 18, 2021

·

2 min read

Biotech Beach

Synedgen Partnership with the University of New South Wales Receives Australian Research Council (ARC) Grant

Synedgen’s CEO, Shenda Baker, gave a related keynote lecture at the Pan Pacific Connective Tissue Societies Symposium on November 25, 2020

December 10, 2020

·

3 min read

Biotech Beach

Synedgen Initiates Clinical Trial Assessing Combination of SynePure and Catasyn for the Treatment of Partial Thickness Burns

Synedgen, a biotechnology company using glycopolymer chemistry to develop therapeutics that enhance and control signaling in the innate immune system, today announced the initiation of a randomized controlled trial (RCT) to test the safety and effectiveness of SynePure™ Wound Cleanser (SynePure) in combination with Catasyn™ Advanced Technology Hydrogel (Catasyn) for the treatment of superficial partial-thickness burn wounds.

August 6, 2021

·

4 min read